Welcome to our dedicated page for Vertex Pharmaceuticals SEC filings (Ticker: VRTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, including current reports on Form 8-K and other key documents. Vertex is a global biotechnology company with approved medicines in cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and a broad clinical pipeline in kidney disease, neuropathic pain, type 1 diabetes and myotonic dystrophy type 1. Its SEC filings give investors and analysts detailed insight into financial performance, risk factors and material events affecting the business.
Recent Form 8-K filings from Vertex have reported quarterly financial results and related guidance under Item 2.02, Results of Operations and Financial Condition. These filings typically reference accompanying press releases that summarize revenue trends, research and development spending and updates across the company’s portfolio, including CFTR modulators such as ALYFTREK and TRIKAFTA, CASGEVY gene-edited cell therapy and JOURNAVX for acute pain. Other 8-K items may address changes in key executives or other corporate developments when they occur.
On Stock Titan, Vertex filings are updated in near real time as they appear on the SEC’s EDGAR system. AI-powered summaries help explain the main points of lengthy documents, so users can quickly understand how new information may relate to VRTX stock without reading every page. For example, AI summaries can highlight key themes in earnings-related 8-Ks, note significant changes in guidance or spending, and point out disclosures related to the progress of pivotal trials or regulatory submissions.
In addition to 8-Ks, users can review Vertex’s annual and quarterly reports when available, as well as any proxy materials and registration statements that may be filed. AI analysis tools on Stock Titan can surface trends across multiple filings, making it easier to track how Vertex’s financial profile and pipeline narrative evolve over time. This page is a useful starting point for anyone researching VRTX from a regulatory and disclosure perspective, complementing price charts, news and other fundamental data.
Vertex Pharmaceuticals EVP and Chief Legal Officer Jonathan Biller sold 945 shares of common stock on February 25, 2026 at $486.35 per share in an open-market trade under a Rule 10b5-1 plan entered on February 24, 2025. On February 24, 2026, 1,144 shares were also disposed of to cover tax withholding, leaving 13,659 directly owned shares.
Vertex Pharmaceuticals executive Edward Morrow Atkinson III reported share sales under a pre-set trading plan. On February 25, 2026, he completed an open-market sale of 668 shares of common stock at $486.35 per share, leaving 18,432 shares held directly afterward.
On February 24, 2026, he disposed of 1,627 shares at $485.11 per share to cover tax obligations by delivering shares, a non-open-market transaction. These transactions were made under a company-approved Rule 10b5-1 trading plan that Mr. Atkinson entered into on August 11, 2025.
Vertex Pharmaceuticals senior executive Kristen Ambrose reported two stock transactions. As SVP & Chief Accounting Officer, she sold 223 shares of Vertex common stock in an open-market sale at an average price of $486.35 per share under a company-approved Rule 10b5-1 trading plan.
She also disposed of 546 shares at $485.11 per share to cover tax obligations by delivering shares rather than cash. After these transactions, she directly held 6,981 shares of Vertex common stock.
Fidelity Brokerage Services LLC filed a Form 144 reporting a proposed sale of common shares of Vertex Pharmaceuticals. The notice lists multiple grant/purchase dates and share lots tied to ESPP purchases and restricted stock vesting, including a line showing 2,394,365 (units) and an NASDAQ listing reference. The filing enumerates specific lot dates and share counts that the filer may sell under Rule 144.
Ourania Tatsis submitted a Form 144 notice reporting a proposed sale related to 260 shares of common stock. The filing lists multiple open‑market dispositions by the same person during the prior three months, including 4,500 shares on 12/03/2025 and 4,500 shares on 01/07/2026, with dollar amounts shown for each trade.
Mark E. Bunnage reported sales of common stock under Rule 144. The filing lists four dispositions: 12/29/2025 — 23 shares for $10,649.00; 02/11/2026 — 2,021 shares for $930,529.03; 02/17/2026 — 2,437 shares for $1,192,814.02; and 02/18/2026 — 1,182 shares for $559,889.76. The transactions are reported as sales by the holder and include a separate 620-share restricted stock vesting on 02/24/2026 noted as compensation.
Vertex Pharmaceuticals reported Form 144 sales by a reporting person. The excerpt lists sales by E Morrey Atkinson of 1,751 common shares on 02/11/2026 for $806,212.93, 2,031 common shares on 02/17/2026 for $994,093.26, and 817 common shares on 02/18/2026 for $386,996.56. The filing also shows 668 common shares tied to a restricted stock vesting on 02/24/2026.
Vertex Pharmaceuticals submitted a Rule 144 notice reporting a sale of 58,613 shares on 02/19/2026 for $27,479,575.26.
The filing also lists restricted stock vesting of 1,846 common shares tied to 02/24/2026 described as compensation, and identifies Fidelity Brokerage Services LLC as the broker.
Vertex Pharmaceuticals reported insider sales by Jonathan P. Biller of Common stock under Rule 144. The filing lists individual transactions including 347 shares on 12/03/2025 for $155,803.00, 1,925 shares on 02/11/2026 for $886,327.75, 988 shares on 02/13/2026 for $493,012.00, 2,476 shares on 02/17/2026 for $1,211,902.96, and 1,244 shares on 02/18/2026 for $589,257.92.
The report shows these dispositions were made from holdings registered with Fidelity Brokerage Services LLC and includes a separate entry for 945 shares vested on 02/24/2026 as restricted stock vesting.
Vertex Pharmaceuticals executive Amit Sachdev reported option exercises and share sales. On February 19, 2026, he exercised stock options covering 23,479 shares at a price of $155.57 per share and 25,026 shares at $187.53 per share, converting them into common stock.
On the same date, he sold a total of 58,613 shares of common stock in multiple open-market transactions at prices ranging from approximately $463.91 to $471.43, under a company-approved Rule 10b5-1 trading plan entered into on November 18, 2025. Following these transactions, he held 58,934 shares directly, plus 882 shares in a 401(k) and 9,301 shares held in a trust.